lestaurtinib (CEP-701) - Teva, Kyowa Kirin
Iomab-B (I-131-apamistamab) - Actinium
Venclexta (venetoclax) - Roche, AbbVie
Xospata (gilteritinib) - Astellas
Tibsovo (ivosidenib) - Agios Pharma
Vanflyta (quizartinib) - Daiichi Sankyo
sapacitabine (CYC682) - Cyclacel
azacitidine - Generic mfg.
decitabine - Generic mfg.
Nexavar (sorafenib) - Bayer, Amgen
Idhifa (enasidenib) - BMS
Rydapt (midostaurin) - Novartis
Daurismo (glasdegib) - Pfizer
crenolanib besylate (ARO-002) - AROG
https://congress-program.ehaweb.org/eha2021/en-US/PublicProgram/NavigateToProgramdetails/94874?pProgramGrade=All&pHideLogin=False&pHidePersonal=False&pShowPrivate=False
 
Jannik Stemler; Nicole Skoetz; Nick de Jonge; Roger Bruggemann; János Sinkó; Alessandro Busca; Zdenek Rácil; Ronen Ben Ami; Vanessa Piechotta; Russell Lewis; Oliver Cornely
 
May 13, 2021
 
Prev Next